Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide belonging to the secretin/glucagon superfamily. First isolated from porcine duodenum by Said and Mutt in 1970, VIP is now recognized as a pleiotropic signaling molecule with roles in circadian rhythm regulation, immune modulation, neuroprotection, and gastrointestinal physiology—making it one of the most broadly studied peptides in biomedical research.
Structure and Receptor Pharmacology
VIP (His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂) adopts an amphipathic α-helical structure in membrane environments. It signals through two class B (secretin family) GPCRs: VPAC1 (widely distributed) and VPAC2 (enriched in CNS, pancreas, and immune cells). Both receptors also bind PACAP (pituitary adenylate cyclase-activating polypeptide), though with different affinity profiles. A third receptor, PAC1, binds PACAP preferentially over VIP.
VPAC1 and VPAC2 couple primarily to Gαs, activating adenylyl cyclase and increasing intracellular cAMP. They also engage Gαq (PLC/IP3/calcium signaling) and Gα12/13 (Rho GTPase pathways) depending on cell type and receptor density. This multi-pathway signaling underlies VIP’s diverse tissue-specific effects.
Circadian Biology
VIP is essential for circadian clock function. In the suprachiasmatic nucleus (SCN)—the master circadian pacemaker—VIP is expressed in the ventral (core) region and is critical for synchronizing the ~20,000 SCN neurons into a coherent circadian rhythm. VIP acts through VPAC2 receptors on neighboring SCN neurons, coupling their individual molecular clocks via cAMP/PKA/CREB signaling that entrains Period gene expression.
VIP knockout mice and VPAC2 knockout mice show severely disrupted circadian rhythms: loss of coordinated SCN firing, disrupted sleep-wake cycles, and blunted hormonal rhythms. These models have been instrumental in understanding how individual cellular oscillators are synchronized into a systems-level circadian output.
Immunomodulatory Research
VIP is recognized as a potent immunomodulatory peptide. It is released from nerve terminals innervating lymphoid organs and from immune cells themselves (Th2 lymphocytes, mast cells). VIP promotes anti-inflammatory and immunoregulatory responses through several mechanisms: inhibition of macrophage TNF-α, IL-6, and IL-12 production via cAMP-mediated suppression of NF-κB; promotion of Th2 cytokine profiles; induction of tolerogenic dendritic cells; and generation of regulatory T cells.
In animal models of autoimmune conditions, VIP and its stable analogs have shown effects in experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis, and inflammatory bowel disease models. These studies utilize both systemic VIP administration and VIP-gene-modified dendritic cell transfer approaches.
Neuroprotection
VIP has demonstrated neuroprotective properties in multiple experimental paradigms. In excitotoxicity models (NMDA, kainic acid), VIP reduces neuronal death through cAMP-dependent pathways that upregulate BDNF, activity-dependent neuroprotective protein (ADNP), and Bcl-2 (anti-apoptotic). ADNP, discovered through VIP research, contains the octapeptide NAP (NAPVSIPQ) which is itself a potent neuroprotective agent now in clinical development.
Gastrointestinal Functions
In the gut, VIP serves as a non-adrenergic, non-cholinergic (NANC) neurotransmitter released from enteric neurons. It relaxes smooth muscle (via cAMP-mediated calcium desensitization), stimulates water and electrolyte secretion from intestinal epithelium (via CFTR chloride channel activation), and promotes pancreatic bicarbonate secretion. VIP-producing tumors (VIPomas) cause profuse watery diarrhea, validating VIP’s secretory role in vivo.
Frequently Asked Questions
What distinguishes VPAC1 from VPAC2 in research contexts?
VPAC1 is widely expressed (lung, liver, intestine, T cells) and mediates many of VIP’s peripheral effects. VPAC2 is enriched in the CNS (especially SCN), pancreatic islets, and smooth muscle. Selective agonists (e.g., [Ala11,22,28]VIP for VPAC1; Ro 25-1553 for VPAC2) and antagonists (PG97-269 for VPAC1; PG99-465 for VPAC2) allow receptor-specific studies.
How is VIP administered in research models?
VIP has a short plasma half-life (approximately 1-2 minutes) due to rapid degradation by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP). Research administration routes include continuous IV infusion, ICV injection for central studies, and osmotic minipumps for chronic paradigms. Stable analogs with D-amino acid substitutions or PEGylation extend the half-life for long-term studies.
What is the relationship between VIP and PACAP?
VIP and PACAP share 68% sequence homology and signal through overlapping receptor systems (VPAC1, VPAC2). PACAP additionally activates the PAC1 receptor, which VIP does not. Both peptides belong to the secretin/glucagon superfamily. In research, distinguishing VIP-specific from PACAP-specific effects requires selective receptor antagonists and knockout models for each receptor subtype.